To tackle the complicated world of neuroendocrine tumors (NETs), Chadi is joined by Pamela Kunz, MD, Director of the Center for GI Cancers at Yale Cancer Center; as well as the Vice Chief of Diversity, Equity, and Inclusion for medical oncology at Yale Cancer Center. Dr. Kunz begins by shedding light on potential reasons for higher incidence of NETs in the past three decades and the boom of FDA approvals in the last decade, as well as the latest therapies and clinical trials with the most potential to move the needle for patient care. Then, Chadi and Dr. Kunz highlight the priorities of a new committee she has helped form for diversity, equity, and inclusion within the institution – including data collection, increasing the diversity of the faculty, and creating a culture of respect.
N/A
Dr. Simrit Parmar, founder of Cellenkos, joins the show to discuss her journey from the lab to the biotech startup world, detailing the inspiration behind launching her company, the challenges of securing funding, and the resilience required to overcome rejections. She shares insights into Cellenkos’ lead product, its progress toward market approval, and the rigorous
Carol Rausch—a healthcare professional, cancer researcher, and former patient with lymphoma—shares how her journey from researcher to patient transformed her understanding of medical language. She discusses the impact of word choice on patients, why certain battle and war metaphors can be harmful, and how language used in clinical settings differs from what resonates with those
Drs. David Braun and Toni Choueiri join to discuss a groundbreaking Nature study on a personalized neoantigen vaccine for adjuvant renal cell carcinoma. They explore the inspiration behind the trial, how the vaccine was developed and administered, and its safety profile. The conversation also covers patient outcomes after 3-4 years, including immune responses and disease
